A Multicenter, Double-blind, Randomized Study to Evaluate the Effects of Tasimelteon vs. Placebo in Participants With Delayed Sleep-Wake Phase Disorder (DSWPD)
Latest Information Update: 31 Jul 2024
At a glance
- Drugs Tasimelteon (Primary)
- Indications Circadian rhythm sleep disorders
- Focus Registrational; Therapeutic Use
- Sponsors Vanda Pharmaceuticals
- 01 Apr 2024 Planned End Date changed from 1 Dec 2023 to 1 Dec 2025.
- 15 Oct 2021 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 15 Oct 2021 Planned primary completion date changed from 1 Dec 2021 to 1 Dec 2022.